These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Clinical utility of plasma miR-371a-3p in germ cell tumors. Mego M; van Agthoven T; Gronesova P; Chovanec M; Miskovska V; Mardiak J; Looijenga LHJ J Cell Mol Med; 2019 Feb; 23(2):1128-1136. PubMed ID: 30536846 [TBL] [Abstract][Full Text] [Related]
13. Refining the serum miR-371a-3p test for viable germ cell tumor detection. Lafin JT; Scarpini CG; Amini A; Konneh B; Howard JM; Gerald T; Nuno M; Piao J; Savelyeva A; Wang Z; Gagan J; Jia L; Lewis CM; Murray S; Sawa YC; Margulis V; Woldu SL; Strand DW; Coleman N; Amatruda JF; Frazier AL; Murray MJ; Bagrodia A Sci Rep; 2023 Jun; 13(1):10558. PubMed ID: 37386046 [TBL] [Abstract][Full Text] [Related]
14. Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study. Dieckmann KP; Radtke A; Geczi L; Matthies C; Anheuser P; Eckardt U; Sommer J; Zengerling F; Trenti E; Pichler R; Belz H; Zastrow S; Winter A; Melchior S; Hammel J; Kranz J; Bolten M; Krege S; Haben B; Loidl W; Ruf CG; Heinzelbecker J; Heidenreich A; Cremers JF; Oing C; Hermanns T; Fankhauser CD; Gillessen S; Reichegger H; Cathomas R; Pichler M; Hentrich M; Eredics K; Lorch A; Wülfing C; Peine S; Wosniok W; Bokemeyer C; Belge G J Clin Oncol; 2019 Jun; 37(16):1412-1423. PubMed ID: 30875280 [TBL] [Abstract][Full Text] [Related]
15. Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer. Lobo J; Leão R; Gillis AJM; van den Berg A; Anson-Cartwright L; Atenafu EG; Kuhathaas K; Chung P; Hansen A; Bedard PL; Jewett MAS; Warde P; O'Malley M; Sweet J; Looijenga LHJ; Hamilton RJ Eur Urol Oncol; 2021 Jun; 4(3):483-491. PubMed ID: 33288479 [TBL] [Abstract][Full Text] [Related]
16. microRNA-371a-3p as informative biomarker for the follow-up of testicular germ cell cancer patients. van Agthoven T; Eijkenboom WMH; Looijenga LHJ Cell Oncol (Dordr); 2017 Aug; 40(4):379-388. PubMed ID: 28612337 [TBL] [Abstract][Full Text] [Related]
17. Circulating MicroRNAs, the Next-Generation Serum Biomarkers in Testicular Germ Cell Tumours: A Systematic Review. Leão R; Albersen M; Looijenga LHJ; Tandstad T; Kollmannsberger C; Murray MJ; Culine S; Coleman N; Belge G; Hamilton RJ; Dieckmann KP Eur Urol; 2021 Oct; 80(4):456-466. PubMed ID: 34175151 [TBL] [Abstract][Full Text] [Related]
18. The Diagnostic Accuracy of miR-371a-3p for Testicular Germ Cell Tumors: A Systematic Review and Meta-Analysis. Liu Q; Lian Q; Lv H; Zhang X; Zhou F Mol Diagn Ther; 2021 May; 25(3):273-281. PubMed ID: 33886084 [TBL] [Abstract][Full Text] [Related]
19. MicroRNA miR-371a-3p - A Novel Serum Biomarker of Testicular Germ Cell Tumors: Evidence for Specificity from Measurements in Testicular Vein Blood and in Neoplastic Hydrocele Fluid. Dieckmann KP; Spiekermann M; Balks T; Ikogho R; Anheuser P; Wosniok W; Loening T; Bullerdiek J; Belge G Urol Int; 2016; 97(1):76-83. PubMed ID: 26989896 [TBL] [Abstract][Full Text] [Related]
20. MiR-371a-3p Serum Levels Are Increased in Recurrence of Testicular Germ Cell Tumor Patients. Terbuch A; Adiprasito JB; Stiegelbauer V; Seles M; Klec C; Pichler GP; Resel M; Posch F; Lembeck AL; Stöger H; Szkandera J; Pummer K; Bauernhofer T; Hutterer GC; Gerger A; Stotz M; Pichler M Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30321995 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]